What I'm proposing was never intended to instantly bring the Nasdaq, it is only intended to give the company a more solid bases for doing so. Bring the O/S to somewhere under 100 million shares gives the company plenty of room for dilutive financing, with a half billion shares authorized, but it also keeps existing shareholders in a position where they hold at least 10% of the shares they once owned 100% of after dilution. A reduction to 1 for 100 or less takes us to owning between 1% and .2% if fully diluted, it may work great for the company, but it kills the investors.

They need to build the company by their actions, gain the patents they're applied for, run clinical trials on patented products to demonstrate efficacy, then partner. Do that, and without a single reverse split we could be on the Nasdaq. If they fail to do this, even if they've achieved the Nasdaq by a bizarre reverse split, they won't be able to stay there.

Don't get me wrong, I'm aware of companies that have done multiple 100 to 1 reverse splits, sometime they're able to even stay on the Nasdaq after doing it, but the only thing they manage to do is issue more shares, than do another reverse split. My point is, the right way to get on the Nasdaq is by building the company by developing patented products that sell, not by doing a R/S than issuing a lot more shares, and doing another R/S. If a small R/S would help, I'd consider it once some success was achieved. Show me one patent that's been approved here in the U.S. and I think we'd be at a level where we could talk about it.

Gary